Apalutamide is used in the treatment of castration-resistant prostate cancer.
A simple, specific, selective, and effective liquid chromatography-tandem mass spectrometry method for quantifying apalutamide and its active metabolite concentration in human plasma was developed and validated according to the FDA and EMA validation guidelines.
